Candel Therapeutics is a leading brand in the field of cancer treatment, specializing in viral immunotherapies. They have revolutionized the cancer treatment paradigm by demonstrating that the immune system can be trained to identify and eliminate tumor cells. Their unique approach combines both anti-tumor and immune-stimulatory components, resulting in an in-situ vaccination effect against injected tumors and uninjected metastases.

Candel Therapeutics is committed to developing viral immunotherapies that target the specific antigens and neoantigens presented when tumor cells break down. By activating both the innate and adaptive immune mechanisms, they aim to create a systemic and sustained anti-cancer effect. This approach has the potential to transform disease outcomes across various indications, from early to late-stage cancer.

With a mission to save, extend, and improve the lives of patients, Candel harnesses the power of their proprietary virus-based approaches to elicit a broad and potent immune response against solid tumors and their metastases. Their leadership team consists of renowned drug developers, viral immunotherapy experts, oncologists, immunologists, and biotech business leaders who are dedicated to translating scientific advancements into effective treatments for patients. Candel Therapeutics is at the forefront of cancer research and is poised to make a significant impact in the field of viral immunotherapy